Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,024 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study.
Li Y, Qi L, Bai H, Sun C, Xu S, Wang Y, Han C, Li Y, Liu L, Cheng X, Liu J, Lei C, Tong Y, Sun M, Yan L, Chen W, Liu X, Liu Q, Xie L, Wang X. Li Y, et al. Among authors: xie l. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0106321. doi: 10.1128/AAC.01063-21. Epub 2021 Sep 7. Antimicrob Agents Chemother. 2021. PMID: 34491805 Free PMC article. Clinical Trial.
Phase I, randomized, double-blind, single-dose study to assess the pharmacokinetics, safety, and immunogenicity of the proposed biosimilar SCT630 and adalimumab in healthy Chinese subjects.
Liu L, Qi L, Lei C, Wang Y, Zhang W, Liu Y, Li P, Bai H, Li Y, Li Y, Liu J, Xie L, Wang X. Liu L, et al. Among authors: xie l. Int Immunopharmacol. 2022 May;106:108599. doi: 10.1016/j.intimp.2022.108599. Epub 2022 Feb 19. Int Immunopharmacol. 2022. PMID: 35193054 Clinical Trial.
A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis.
Yu C, Zhang F, Ding Y, Li Y, Zhao Y, Gu J, Guo S, Pan W, Jin H, Sun Q, Kang X, Yang Q, Jiang X, Song Z, Lu Q, Pang X, Kuang Y, Deng D, Li Y, Zhang C, Tao J, Xie L, Wang Y, Wang J, Wang G. Yu C, et al. Among authors: xie l. Int Immunopharmacol. 2022 Nov;112:109248. doi: 10.1016/j.intimp.2022.109248. Epub 2022 Sep 18. Int Immunopharmacol. 2022. PMID: 36126411 Clinical Trial.
Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial.
Hannawi S, Saifeldin L, Abuquta A, Alamadi A, Mahmoud SA, Hassan A, Liu D, Yan L, Xie L. Hannawi S, et al. Among authors: xie l. EBioMedicine. 2023 Jan;87:104386. doi: 10.1016/j.ebiom.2022.104386. Epub 2022 Dec 5. EBioMedicine. 2023. PMID: 36470077 Free PMC article. Clinical Trial.
A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera®) in patients with CD20-positive B-cell non-Hodgkin lymphoma.
Han X, Zhang M, Wang H, Zhang Q, Li W, Hao M, Gao Y, Jin J, Ren H, Tang Y, Hong X, Ke X, Su H, Gui L, Luo J, Xie L, Gai W, Shi Y. Han X, et al. Among authors: xie l. Chin J Cancer Res. 2022 Dec 30;34(6):601-611. doi: 10.21147/j.issn.1000-9604.2022.06.08. Chin J Cancer Res. 2022. PMID: 36714342 Free PMC article.
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera® ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial.
Shi Y, Zhang Q, Hong X, Wang Z, Gao Y, Zou L, Cen H, Gui L, Li Y, Feng J, Wang Z, Zhang M, Jin C, Zhang W, Hu J, Zheng C, Zheng Z, Zhang L, Chen S, Huang Y, Tang Y, Gao Y, Hao M, Li X, Chang C, Yang H, Wu H, Shen L, Ke X, Zhang L, Xi Y, Yang L, Xie L, Gai W, Ji Y. Shi Y, et al. Among authors: xie l. Hematol Oncol. 2022 Dec;40(5):930-940. doi: 10.1002/hon.3054. Epub 2022 Aug 12. Hematol Oncol. 2022. PMID: 35858181 Clinical Trial.
12,024 results
You have reached the last available page of results. Please see the User Guide for more information.